Literature DB >> 22028445

Endothelial dysfunction in a rat model of PCOS: evidence of increased vasoconstrictor prostanoid activity.

Jennifer Keller1, Maurizio Mandala, Peter Casson, George Osol.   

Abstract

Clinical research demonstrates an association between polycystic ovary syndrome (PCOS) and endothelial dysfunction, a pathological state widely believed to be a hallmark of vascular disease; the underlying pathways, however, have not been defined. The purpose of this study was to characterize endothelial function in resistance arteries in a novel rat model of PCOS. Female rats were randomized at 3-4 wk to implantation of a 7.5-mg, 90-d dihydrotestosterone (DHT) pellet or a matched placebo. At 15-16 wk, experiments were performed on isolated mesenteric resistance arteries using a pressurized arteriograph. Endothelial function was assessed by the vasodilatory response of preconstricted arteries to acetylcholine (ACh) in the absence and presence of inhibitors for cyclooxygenase (indomethacin) and the thromboxane prostanoid receptor antagonist (SQ29,548). Distensibility was evaluated by measuring vessel diameter from 3-100 mm Hg, and elastin/collagen content was calculated on formalin-fixed vessels. Serum steroid levels were analyzed by sensitive RIA. DHT-induced PCOS rats were heavier, cycled irregularly, and had elevated blood pressure and smaller arterial lumens than controls. Furthermore, DHT vessels showed significantly reduced vasodilatory efficacy to ACh (with no change in sensitivity), reduced distensibility, and increased elastin content compared with controls. Within DHT animals, maximal dilation correlated negatively to DHT levels (r = -0.72) but not to body weight. Preincubation with either indomethacin or SC29,548 abrogated the dysfunction and restored full efficacy to ACh (P < 0.05). This is the first report to demonstrate the presence of endothelial dysfunction in a hyperandrogenic rat model of PCOS and to identify the role of vasoconstrictor prostanoids, allowing for more targeted research regarding the development of disease and potential therapeutic interventions.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22028445     DOI: 10.1210/en.2011-1424

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  5 in total

1.  Cardiac fatty acid uptake and metabolism in the rat model of polycystic ovary syndrome.

Authors:  Snežana Tepavčević; Danijela Vojnović Milutinović; Djuro Macut; Mojca Stojiljković; Marina Nikolić; Ivana Božić-Antić; Tijana Ćulafić; Jelica Bjekić-Macut; Gordana Matić; Goran Korićanac
Journal:  Endocrine       Date:  2015-02-22       Impact factor: 3.633

2.  Inhibition of Col6a5 Improve Lipid Metabolism Disorder in Dihydrotestosterone-Induced Hyperandrogenic Mice.

Authors:  Li-Feng Sun; Ya-Li Yang; Mei-Yue Wang; Hua-Shan Zhao; Tian-Xia Xiao; Meng-Xia Li; Bao-Bei Wang; Chen Huang; Pei-Gen Ren; Jian V Zhang
Journal:  Front Cell Dev Biol       Date:  2021-05-24

3.  Liraglutide improves hypertension and metabolic perturbation in a rat model of polycystic ovarian syndrome.

Authors:  Vanessa Hoang; Jiangjiang Bi; Sheba M Mohankumar; Arpita K Vyas
Journal:  PLoS One       Date:  2015-05-26       Impact factor: 3.240

Review 4.  Animal models of polycystic ovary syndrome: A review of hormone-induced rodent models focused on hypothalamus-pituitary-ovary axis and neuropeptides.

Authors:  Satoko Osuka; Natsuki Nakanishi; Tomohiko Murase; Tomoko Nakamura; Maki Goto; Akira Iwase; Fumitaka Kikkawa
Journal:  Reprod Med Biol       Date:  2018-12-28

5.  Effect of cold stress on ovarian & uterine microcirculation in rats and the role of endothelin system.

Authors:  Di Wang; Xiumei Cheng; Huimin Fang; Yanqing Ren; Xinhua Li; Weiwei Ren; Bing Xue; Cairui Yang
Journal:  Reprod Biol Endocrinol       Date:  2020-04-14       Impact factor: 5.211

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.